AMENDMENTS TO THE CLAIMS

1.-11. (Cancel)

12. (Original) A method comprising administering to a cell a Bik polypeptide having an amino acid substitution.

13. (Original) The method of claim 12, wherein the amino acid substitution is at Thr^{33}, Ser^{35}, or both $Thr^{33}$and Ser^{35}.

14. (Original) The method of claim 13, wherein the substitution is a Thr^{33} to Asp^{33} substitution.

15. (Original) The method of claim 13, wherein the substitution is a Ser^{35} to Asp^{35} substitution.

16. (Original) The method of claim 12, wherein the polypeptide further comprises a protein transduction domain.

17. (Original) The method of claim 12, wherein the cell is comprised in an animal.

18. (Original) The method of claim 17, wherein the animal is a human.

19. (Original) The method of claim 18, wherein the human has a proliferative cell disorder.

20. (Original) The method of claim 19, wherein the proliferative cell disorder is cancer.

21. (Original) The method of claim 20, wherein the cancer is breast cancer, prostate cancer, ovarian cancer, sarcoma, lung cancer, brain cancer, pancreatic cancer, liver cancer, bladder cancer, gastrointestinal cancer, leukemia, lymphoma, or myeloma.

22. (Original) The method of claim 20, wherein the cancer is estrogen receptor positive, is EGF receptor overexpressing, is *Her2/neu-*

overexpressing, is not *Her-2/neu*-overexpressing, is Akt overexpressing, is angrogen independent, or is androgen dependent.

23. (Original) The method of claim 20, wherein the cancer is a solid tumors, such as, for example, sarcoma, lung, brain, pancreatic, liver, bladder, gastrointestinal cancers, or hematologic malignancies, such as leukemia, lymphoma, and myeloma

24. (Original) The method of claim 20, wherein the proliferative cell disorder is restenosis.

25. (Original) The method of claim 12, wherein the polypeptide is comprised in pharmacologically acceptable excipient.

26. (Original) The method of claim 25, wherein the polypeptide is complexed with a lipid.

27. (Withdrawn) The method of claim 13, wherein administering to the cell a Bik polypeptide having an amino acid substitution at Thr^{33} comprises administering to the individual a nucleic acid encoding a Bik polypeptide having an amino acid substitution at Thr^{33}.

28. (Withdrawn) The method of claim 27, wherein the expression of the nucleic acid is regulated by a tissue-specific control sequence.

29. (Withdrawn) The method of claim 27, wherein the nucleic acid is comprised in a plasmid, a retroviral vector, an adenoviral vector, an adeno-associated viral vector, or a liposome.

30. (Withdrawn) The method of claim 27, wherein the nucleic acid is dispersed in a pharmacologically acceptable excipient.

31. (Withdrawn) The method of claim 28, wherein the tissue-specific control sequence is a breast cancer-specific control sequence.

32. (Withdrawn) The method of claim 28, wherein the tissue-specific control sequence is a prostate cancer-specific control sequence.

33. (Withdrawn) The method of claim 28, wherein the tissue-specific control sequence is a pancreatic cancer-specific control sequence.

34. (Withdrawn) The method of claim 13, wherein administering to the cell a Bik polypeptide having an amino acid substitution at Ser^{35} comprises administering to the individual a nucleic acid encoding a Bik polypeptide having an amino acid substitution at Ser^{35}.

35. (Withdrawn) The method of claim 34, wherein the expression of the nucleic acid is regulated by a tissue-specific control sequence.

36. (Withdrawn) The method of claim 34, wherein the nucleic acid is comprised in a plasmid, a retroviral vector, an adenoviral vector, an adeno-associated viral vector, or a liposome.

37. (Withdrawn) The method of claim 34, wherein the nucleic acid is dispersed in a pharmacologically acceptable excipient.

38. (Withdrawn) The method of claim 35, wherein the tissue-specific control sequence is a breast cancer-specific control sequence.

39. (Withdrawn) The method of claim 35, wherein the tissue-specific control sequence is a prostate cancer-specific control sequence.

40. (Withdrawn) The method of claim 35, wherein the tissue-specific control sequence is a pancreatic cancer-specific control sequence.

41. (Original) The method of claim 12, further defined as a method of preventing growth of a cell in an individual.